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Summary
The pathogenesis of Pseudomonas aeruginosa (PA) infection is multifactorial and depends mainly 
on two types of virulence determinants: virulence factors involved in acute infections and 
membrane bound factors, and virulence factors involved in chronic infections. The aim of this 
laboratory-based study was to analyse the resistance and virulence of PA strains isolated from 
different types of infections in hospitalised and non-hospitalised patients in Southern Poland. 
Non-repetitive samples from urinary tract infections (UTI), bloodstream infections (BSI) and 
pneumonia (PNU) were collected. Isolates were screened for the presence of virulence fac-
tors by PCR method. Antimicrobial susceptibility testing was performed using disc diffusion 
method. Metallo-beta-lactamases (MBLs) were detected using an imipenem-EDTA double-disc 
synergy test.
There were 232 specimens collected: UTI-152, PNU-69, BSI-11. Fifty-one (22%) strains were 
classified as multidrug resistant (MDR), 23 (10%) as extensively-drug resistant (XDR). MDR/
XDR strains were more frequently isolated from pneumonia (OR = 2.28). The prevalence values 
for the genes of effector proteins were 82.8% for exoS, 89% for exoY, and 24% for exoU. The 
simultaneous detection of four effector proteins was confirmed in 10.4% of the strains. pilB 
was more prevalent in isolates from the elderly (p=0.013). lasB occurred more frequently in 
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INTRODUCTION
Pseudomonas aeruginosa (PA) is an opportunistic path-
ogen that is a common cause of hospital acquired 
infections. Infection with PA may be associated with 
significant morbidity and mortality. PA adapts easily to 
environmental changes, rapidly develops resistance, and 
produces a wide variety of virulence factors. The patho-
genesis of PA infection is multifactorial and depends 
mainly on two types of virulence determinants: 
• virulence factors involved in acute infections (usually 
secreted) and membrane bound factors; 
• virulence factors involved in chronic infections (i.e. 
siderophores). 
Virulence traits may vary between strains of PA; these 
traits vary with respect to the site of infection [5, 7, 22, 39].
PA has several known virulence factors. Elastase, encoded 
by the lasB gene, is a metalloprotease that degrades elas-
tin and collagen. Elastase inactivates human immunoglob-
ulin G and several complement components [23]. Alkaline 
protease (AprA) is a zinc metalloprotease. AprA expression 
correlates with PA infections of the eye, gastrointestinal 
tract and wounds [23]. It can also degrade many biologically 
important proteins (i.e. casein, gelatin, and complement 
factors) [14, 19]. Type 4 fimbrial assembly protein, PilB, 
is essential for the synthesis of type IV pili. PilA is a type 
IV pilus protein. The type III secretion system is another 
important PA virulence determinant [10]. This system uses 
complex secretion and translocation machinery to inject 
a set of factors (effector proteins) directly into the cyto-
plasm of eukaryotic cells. Four of these effector proteins 
have been identified: ExoS, ExoT, ExoU, and ExoY. All have 
toxic effects on cells. ExoS has cytotoxic activity, induces 
apoptosis, and modulates bacterial phagocytosis and inva-
sion into host cells [17, 37]. ExoT is involved in inhibiting 
the rate of wound healing and inhibits bacterial internali-
zation functions of epithelial cells and macrophages [37]. 
ExoU is an acute cytolytic factor that mediates rapid cell 
lysis [36]. ExoY is an adenylate cyclase that causes round-
ing of certain cell types [36]. PA isolates that possess the 
exoU effector protein gene are referred to as having a cyto-
toxic phenotype and those with the exoS effector protein 
gene have an invasive phenotype [40]. It has been proved 
by Pena et al. that exoU+ genotype is independently asso-
ciated with increased risk of early mortality of PA blood-
stream infections, so detecting the presence of these 
virulence genes may lead to easier identification of poten-
tially lethal infections [15, 24, 28].
Approximately 95% of PA strains produce pyocyanin, 
which is a blue-pigmented phenazine derivative that has 
a role in virulence [21]. Pyocyanin has a role in the pul-
monary tissue damage that occurs during PA infection. 
Pyocyanin is produced from chorismic acid via the phen-
azine pathway, which consists of nine proteins encoded 
by a gene cluster [12]. Phenazine-1-carboxylic acid is the 
initial phenazine formed and is converted to pyocyanin 
in two steps that are catalysed by the enzymes PhzM and 
PhzS. PhzM is only active in the presence of PhzS [12]. 
Our previously published results indicated that some 
virulence factors may be associated with the age of the 
treated patients [26]. Additional samples are needed to 
study this relationship, because the characteristics of 
virulence traits among the PA strains isolated from dif-
ferent populations and sites of infection have not been 
comprehensively studied. 
The aim of this laboratory-based study was to analyse the 
resistance and virulence of PA strains isolated from differ-
ent types of infections in hospitalised and non-hospitalised 
PNU (p=0.048). Three of the genes were more prevalent in isolates from patients hospitalised 
in ICU (lasB (p=0.017), aprA (p=0.022), phzS (p=0.039)). 
Understanding the contribution of selected virulence genes to the outcome of an infection 
may be important for the therapeutic management of patients infected with PA. Simultane-
ous detection of virulence factors and antimicrobial resistance might be particularly useful 
because both are clinically important during an infection. 
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PCR analysis was performed using previously published 
primers and conditions [2, 9]. The 2xPCR Master Mix 
(A&A Biotechnology, Poland) was used for PCR reactions. 
PCR products were separated on 1.5% agarose gel for 
60 min at 90V, stained with ethidium bromide (Sigma-
Aldrich, Munich, Germany) and detected using ultravio-
let transillumination. 
Susceptibility testing
Antimicrobial susceptibility testing was performed for 
all strains using Mueller-Hinton agar plates and fol-
lowing the current guidelines of the European Com-
mittee on Antimicrobial Susceptibility testing for the 
disc diffusion method (clinical breakpoint table v.5.0; 
http://www.eucast.org/clinical_breakpoints/, accessed 
5.06.2015). Gentamycin, tobramycin, amikacin, netilm-
icin, imipenem, meropenem, doripenem, ceftazidime, 
cefepime, ciprofloxacin, levofloxacin, ticarcillin/clavu-
lanic acid, and piperacillin/tazobactam discs were used 
for the testing. All discs were obtained from Oxoid Lim-
ited (Hampshire, UK). Resistant and intermediate strains 
were grouped together as drug-resistant. Metallo-beta-
lactamases (MBLs) were detected using the imipenem-
EDTA double-disc synergy method. Enlargement zone 
around IMP disc in the direction of EDTA disc indicated 
the presence of MBLs [18]. Multi-drug resistant (MDR) 
strains were defined as those strains that were not sus-
ceptible to at least one antimicrobial in at least three 
different antimicrobial classes. Extensively-drug resist-
ant (XDR) strains were defined as those strains that were 
susceptible to no more than two antimicrobial classes 
[20]. 
STATISTICAL ANALYSES
Analyses were performed using Statsoft Statistical soft-
ware (version 10, StatSoft Inc., Tulsa, OK, USA). The 
distributions of continuous variables were tested for 
normality using the Shapiro-Wilk test. Because the val-
ues for the tested variables did not follow normal distri-
bution, the data was summarised as median, and as the 
25th (Q1) and the 75th (Q3) percentile values, and were 
tested using the nonparametric Mann-Whitney U test. 
For dichotomous variables, a Chi-square test was used for 
expected frequencies >10, a Chi-square test with Yates’ 
correction was used for expected frequencies between 5 
and 10, and a Chi-square test with confirmation by Fish-
er’s exact test was used for expected frequencies ≤5. 
Logistic regression analysis was used to evaluate the 
effects of factors on the presence or absence of MDR/
XDR infection. The model was created using a backward 
stepwise regression method with v-fold cross-evalua-
tion. We began with a set of 17 variables, including sex, 
age, site of infection (BSI, UTI, or PNU), sample source 
(HC – home care patients, ICU, hospitalised on non-ICU, 
or LTCF), and all of the studied virulence genes (present 
vs. absent). Age was included as a categorical variable 
because the relationship between the logarithm of the 
chance and continuous predictor was non-linear (p(LR) = 
patients in southern Poland. We focused on the prevalence 
of particular virulence genes and their associations with 
the patient group, infection site, and the degree of antimi-
crobial resistance of individual PA strains. 
MATERIALS AND METHODS 
Ethics
This work was approved by the Bioethics Committee of 
Jagiellonian University Medical College (Chairperson Prof. 
Piotr Thor; no. KBET/312/B/2012 and KBET/362/B/2012). 
All data was anonymized before analysis.
Population description
Non-repetitive samples that represented different types 
of infections (urinary tract infections (UTIs), bloodstream 
infections (BSIs), and pneumonia (PNU)) were collected 
from hospitalised patients (12 hospitals), from residents 
of long-term care facilities, and from non-hospitalised 
patients in the south of Poland (Malopolska and Sile-
sia). Patients were classified as: (1) long-term care facil-
ity (LTCF) residents, (2) patients hospitalized in intensive 
care units (ICUs), (3) patients hospitalized in non-ICU 
wards, or, (4) patients receiving home care (HC) (i.e. out-
patients) whose infections were diagnosed by a physician.
Samples were collected in collaboration with the KOR-
LAB NZOZ, Ruda Slaska, Poland and the microbiological 
laboratory of St. Barbara’s Regional Hospital in Sos-
nowiec, Poland, between 1 January 2013 and 31 Decem-
ber 2013. Relevant patient information (e.g. age, sex, 
type of infection (polymicrobial or monomicrobial for 
UTI and PNU), and place of treatment of the infection) 
was also collected. 
Bacterial isolates 
Specimens were collected from patients when symptoms 
of infection first occurred. Microbiological examinations 
were performed on urine, blood, sputum, tracheobron-
chial aspirates, and bronchoalveolar lavage fluid when 
these types of samples were available. Standard methods 
and the semi-automatic Phoenix Automated Microbiol-
ogy System (Becton-Dickinson BD, Franklin Lakes, NJ, 
USA) were used to identify microorganisms. 
DNA extraction
DNA templates were extracted from liquid culture in 
tryptic soy broth (BioCorp) (37oC, 18 h) using a Genomic 
Mini kit (A&A Biotechnology, Gdynia, Poland), according 
to the manufacturer’s instructions. 
Screening for the virulence genes 
Isolates were screened for the presence of major viru-
lence factors that are often found in PA (i.e. lasB, exoS, 
exoT, exoU, exoY, pilA, aprA, pilB, phzM, phzS). 
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were more common in men than in women (5.6% men 
vs. 2.8% women). The results were similar for PNU infec-
tions (34.2% men vs. 19.7% women). The opposite trend 
was observed for UTIs, which were present in 77.5% 
of the female patients, and in only 60.3% of the male 
patients. The frequencies of samples of different origin 
and from different infection sites were distributed une-
venly within each sex group in a statistically significant 
manner (p = 0.024 and 0.038, respectively).
Bacterial isolates
Bacterial isolates accounted for: 152 urine isolates 
(65.6%), 69 pneumonia isolates (29.7%), and 11 isolates 
from bloodstream infections (4.7%) (Table 1).
Susceptibility testing
MBLs were detected in 24 (10.3%) isolates: in 10 isolates 
from UTI (4.3%), 12 from PNU (5.2%) and 2 from BSI (0.8%). 
Isolates were classified as MDR, XDR, or as not resistant. 
Fifty-one (22%) of the strains were classified as MDR, 23 
(10%) as XDR, and 158 (68%) as not resistant. MDR and 
XDR strains occurred more frequently in males com-
pared with females (36% vs. 22.5%, respectively, p=0.04; 
odds ratio (OR) 95% confidence interval (95%CI) = 1.94; 
(1.02; 3.68)). 
MDR and XDR strains were more frequently isolated 
from PNU (44.9% of the strains) samples compared with 
samples from other types of infections (27.0% of urine 
strains, 18.2% of blood strains; p=0.019; OR (95%CI) = 2.28 
(1.26; 4.10)). 
0.02). The model contained only two statistically signifi-
cant variables and the distribution of probabilities pre-
dicted by the model did not differ significantly from the 
results observed from the sample (Hosmer Lemeshow 
test = 0.5189, p-value = 0.4712). A p-value < 0.05 was con-
sidered to indicate a statistically significant result.
RESULTS
Population description
The study population consisted of 232 patients. From 
these patients, 232 non-repetitive strains of PA were iso-
lated (Table 1). We included in the study one strain for each 
patient, in case where a second or a third strain was iso-
lated from the same patient, these repetitive strains were 
identical to the first isolate and rejected from the study.
The analysis of the population data revealed that the 
median (Q1; Q3) age was 64 years (47; 72) (Table 1). 
Thirty-one percent of the population was female. Inpa-
tients accounted for 67% (n=155) of the population; 19% 
of these were hospitalised in ICUs (n=45), and 4% were 
the residents of LTCFs (n=10). 
Most of the samples from both sexes originated from 
patients hospitalized in regular hospital wards, and 
relatively more women than men were hospitalised 
in those settings (52.0% women vs. 39.8% men). More 
women than men were residents of LTCFs (5.6% women 
vs. 3.7% men). In contrast, a greater proportion of male 
patients were hospitalised in ICUs (24.2% men vs. 8.5% 
women). Isolates originating from blood infections rep-
resented the minority of the studied isolates, but they 
Table 1. Population data. Differences between strains isolated from different sites of infection
Infection site/
Characteristics
BSI n=11
[number/%]
UTI n=152
[number/%]
PNU n=69 [number/%] P-value
Age (years), median; Q1-Q3 50; 39-68 64; 46-76 64; 54-71
Age categories
0-17 1 9.1 27 17.8 0 0
<0.001
18-60 5 45.5 41 27.0 24 34.8
61-80 4 36.4 64 42.1 40 58.0
>80 1 9.1 20 13.2 5 7.2
Origin
HC 0 0 69 45.4 7 10.1
<0.001
LTCF 0 0 5 3.3 5 7.2
Hospital, excluding ICU 2 18.2 69 45.4 30 43.5
ICU 9 81.8 9 5.9 27 39.1
Sex
Male 9 81.8 97 63.8 55 79.7
0.038
Female 2 18.2 55 36.2 14 20.3
BSI – bloodstream infection, UTI – urinary tract infection, PNU - pneumonia, Q1-Q3 – quartile, HC – home care, LTCF 
– long term care facility, ICU – intensive care unit
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degradation of human immunologically-competent mol-
ecules, was present in 79% (n=183) of the isolates. 
The presence of pilB gene was associated with patient 
age (Table 3). Three of the genes were more prevalent 
in isolates from patients hospitalised in ICUs (i.e. lasB 
(p=0.017), aprA (p=0.022), and phzS (p=0.039)). The fre-
quency of the exoU and exoS genes was higher among 
inpatients and outpatients (p=0.018) (Figure 1).
The presence of a specific virulence gene was not corre-
lated with MDR or XDR phenotype. The odds of having 
an MDR or XDR infection were also two times greater 
if the isolate was from a PNU compared with a UTI (OR 
(95%CI) = 2.105 (1.12; 3.94)). This association was not pre-
sent in blood infections (OR (95%CI)= 0.55 (0.19; 1.59)). 
No correlation was found between the presence of any 
of the type III secretion proteins and the presence of 
MBL phenotype nor was there any resistance found to 
imipenem or ciprofloxacin. 
DISCUSSION
Non-fermentative, Gram-negative bacilli inhabit many 
reservoirs in hospitals and have developed resistance to 
many commonly used antibiotics. These characteristics 
have led to these bacteria becoming prevalent in hospi-
tal-acquired infections (HAI) during the past 50 years. The 
virulence and frequency (10–22% of all HAI, independent 
of patient age) of PA have been important factors associ-
ated with the increased use of antipseudomonal beta-lac-
tam antibiotics and quinolones as presumptive therapies 
in cases in which PA is the suspected aetiology [11, 33]. 
MDR and XDR strains occurred less frequently among 
younger patients (<17 years of age; 7.1%; p = 0.003) com-
pared with older patients (OR (95%CI) = 0.14 (0.03; 0.61)). 
These strains were also isolated less frequently from 
patients in home-care (25.0%), compared with hospital-
ised patients (both ICU and non-ICU; 33.5%) or residents 
of LTCFs (60.0%).
Virulence factor screening
The most prevalent virulence genes were phzM, and 
exoT, which were detected in 221 (95.2%) and 219 (94.4%) 
of the isolates, respectively. The prevalence values for 
the remaining four genes for effector proteins were 
82.8% (n=193) for exoS, 89% (n=206) for exoY, and 24% 
(n=56) for exoU. Approximately 11% of the strains con-
tained both exoS and exoU genes. exoU and exoS simulta-
neously were present in 16 UTI strains (10.5%), 5 strains 
coming from BSI (45.5%) and 4 strains from pneumonia 
(6%). The simultaneous detection of all four effector pro-
teins was confirmed in 10.4% of the strains.
aprA was present in 169 (73%) of the isolates and was 
more prevalent in isolates from patients with BSI 
(p=0.0007). pilB, which confers twitching motility, was 
confirmed in 7 (3%) of the isolates. pilA was found in 59 
(25%) of the isolates. pilB was more prevalent in isolates 
from older patients (age >80 years, p=0.013). phzS was 
present in 86% (n=199) of the isolates. The two phena-
zine genes (phzM and phzS) were also detected more fre-
quently in the isolates from BSI (p=0.001 and p=0.0004, 
respectively). lasB occurred more frequently in the iso-
lates originating from PNU (p=0.048) (Table 2). The gene 
for this factor, which is involved in pathogenesis via its 
Table 2. Distributions of virulence genes of P. aeruginosa strains with respect to site of infection
Site of the infection
BSI 
(n = 11)
UTI 
(n = 152)
PNU 
(n = 69) P value
Total 
(n = 232)
n % n % n % n (%)
pilA 2 18% 35 23% 22 32% 0.35 59 (25.4)
pilB 0 0% 7 5% 0 0% 0.16 7 (3.0)
lasB 8 73% 114 75% 61 88% <0.05 183 (78.9)
exoS 11 100% 137 90% 57 83% 0.15 205(88.4)
exoT 11 100% 146 96% 62 90% 0.19 219 (94.4)
exoU 5 45% 38 25% 19 28% 0.32 62 (26.7)
exoY 11 100% 135 89% 60 87% 0.58 206 (88.4)
aprA 10 91% 99 65% 60 87% <0.01 169 (72.8)
phzM 11 100% 150 99% 60 87% <0.01          221 (95.2)
phzS 11 100% 121 80% 67 97% <0.01 199 (85.8)
BSI – strains from bloodstream infections; UTI - strains from urinary tract infections; PNU – strains from pneumonia; 
pilA - type IV pilus protein; pilB - type IV pili; lasB – elastase; exoS, exoT, exoU, exoY - the type III secretion system; aprA 
- alkaline protease; phzM, phzS – enzymes that catalyse the conversion of phenazine-1-carboxylic acid into pyocyanin. 
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UTI and decreased for pneumonia (21% in 1997 and 17% 
in 2010) nosocomial infections [27, 32]. The total preva-
lence of PA in ICU-acquired pneumonia cases was 16.6% 
in 2014. According to the European Centre for Disease 
Prevention and Control (ECDC) (Annual Epidemiologi-
cal Report 2014 - Antimicrobial resistance and health-
care-associated infections; http://ecdc.europa.eu/), PA 
was the microorganism most frequently isolated from 
The proportion of PA as a cause of nosocomial BSI has 
increased by nearly 30% in recent years. According to 
the WHO National Health and Nutrition Survey, the pro-
portion of PA infections was approximately 3% between 
1992 and 1997 in the U.S., and was 3.8% during 2009-2010. 
PA is one of the most important Gram-negative bacteria. 
It is the second most common etiological agent isolated 
from BSIs. The proportions of PA appear to be stable for 
 
Fig. 1. Distribution of virulence genes, by type of patient care. (ICU: intensive care unit; HOSP: patient hospitalised, non-ICU; HC: home care; LTCF: long term care 
facility) * indicates a statistically significant result
Table 3. Distribution of virulence genes of P. aeruginosa strains, with respect to age group 
Age groups [years]
0-17
(n = 28)
18-60
(n = 70)
61-80
(n = 108)
>80
(n = 26) P value
n % n % n % N %
pilA 6 21% 25 36% 20 19% 8 31% 0.11
pilB 0 0% 1 1% 2 2% 4 15% 0.01
lasB 23 82% 60 86% 81 75% 19 73% 0.45
exoS 23 82% 55 79% 91 84% 24 92% 0.46
exoT 25 89% 66 94% 102 94% 26 100% 0.41
exoU 5 18% 16 23% 30 28% 5 19% 0.67
exoY 27 96% 65 93% 92 85% 22 85% 0.21
aprA 18 64% 54 77% 78 72% 19 73% 0.76
phzM 28 100% 67 96% 100 93% 26 100% 0.31
phzS 23 82% 59 84% 94 87% 23 88% 0.86
pilA - type IV pilus protein; pilB - type IV pili; lasB – elastase; exoS, exoT, exoU, exoY - the type III secretion system; aprA 
- alkaline protease; phzM, phzS – enzymes that catalyse the conversion of phenazine-1-carboxylic acid into pyocyanin. 
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be relatively low, additionally this gene has proved to be 
relatively rare: approximately one-fourth of the isolates 
in our study possessed the pilA gene.
Elastase, which is encoded by lasB, is a secreted proteolytic 
enzyme with a wide range of substrates. The frequency of 
the lasB gene was quite high (almost 80% of the isolates), 
and this gene was more frequent among the PNU strains. 
Other investigators have found that even higher percent-
ages of PA strains are positive for this gene. For example, 
Mitov et al. found that up to 100.0% of PA strains are posi-
tive for the lasB gene, independent of the site of isolation 
[22]. Our results indicated that patients undergoing hos-
pitalization in ICUs had a higher risk of infection with lasB 
gene strains, compared with outpatients or patients from 
regular hospital wards. 
The prevalence of effector proteins was quite high for 
exoT, and exoY, which were present in almost all of the 
strains that were isolated from the study population. 
ExoS was a bit less prevalent (found in 82.8% of the 
strains). Only the gene for ExoU, which is the most cyto-
toxic of the type III secretion proteins, was less preva-
lent - detected in about one-fourth of the isolates, but 
it may be worrisome. This frequency is higher than 
reported by other researchers [8, 24].
ExoU gene is associated with ST235 strains [38]. Stud-
ies performed in the United States revealed the pres-
ence of associations between type III secretory proteins 
and morbidity and mortality in PA-infected patients [28]. 
Secretion of ExoU is a marker for highly virulent strains 
obtained from patients with hospital-acquired pneumo-
nia [31]. Detection of these genes or their products during 
an infection may be clinically meaningful, and knowledge 
of this feature of infections characteristic for specific 
geographic areas appears to be particularly important 
for patient prognosis. We found that the exoU gene was 
more frequent in the strains isolated from BSIs. It has 
been proven in 2015 by Pena et al. that exoU+ genotype is 
associated with increased risk of mortality of bloodstream 
infections caused by PA [24]. What is more, it has been 
proven that highly virulent strains containing the exoU 
gene of the type III secretion system are more likely to 
be FQ-resistant than strains containing the exoS gene [1].
All tested strains contained at least one gene for the 
effector protein and approximately 11% of the strains 
contained both the exoS and exoU genes. Published 
results for the frequency of this genetic pattern are 
inconsistent. Feltman found that simultaneous detec-
tion of exoS and exoU was rare [7]. Others have found 
that it is frequent [9, 22]. The ubiquity of these genes is 
consistent with their important roles in PA virulence. An 
increase in the prevalence of strains with these charac-
teristics might present a potential clinical threat to the 
health of hospital populations. Our previous data sug-
gest, that the presence of exoU gene is associated with 
ST235 strains [25]. But in the case of 232 strains, we were 
not able to perform MLST on such scale. We also found 
HAIs in 2014. It was also frequently isolated from ICU-
acquired BSIs (8.2%) and UTIs (14.1%) that occurred in 
hospitals in European countries. 
The results of our study indicated that there were sig-
nificant correlations between some virulence genes and 
sources of infection. More studies are needed to determine 
the specific roles of these genes in the different clinical 
infections caused by PA. The differences in the distribu-
tions of some genes suggested that some strains adapted 
more effectively to the specific conditions that were pre-
sent during the infection of a specific site. However, the 
results of the statistical analysis also indicated that varia-
tions in the distribution of virulence genes with respect to 
origin were not significant. These results were similar to 
the results obtained by other investigators [13, 19, 29]. 
The correlation between high drug-resistance and 
highly virulent phenotypes is controversial [6]. There is 
an interaction between virulence and resistance within 
bacteria, and the associated biological costs depend on 
factors including the bacterial species involved, viru-
lence and resistance mechanisms, the ecological niche, 
and host characteristics [3]. Our results indicated that 
the percentages of all virulence genes for the MDR or 
XDR phenotypes and the non-resistant strains were 
similar. These results supported the hypothesis that 
virulence and resistance are unrelated; however, our 
observation does not apply to the whole spectrum of 
virulence, only to the examined 10 virulence genes. 
The PA strains isolated from blood cultures were more vir-
ulent compared with the strains isolated from other sites 
of infection. In our study, the high incidence of virulence 
genes among PA isolates from bloodstream infections may 
be due to the relatively small number of these isolates. Gen-
erally, bacteria might have been exposed to stressful con-
ditions within the host’s vascular system [35]. Enhanced 
virulence might be a viable defence strategy in this envi-
ronment of activated immune cells, other host-protective 
mechanisms, and limited major nutrients (i.e. iron). 
The frequency of the gene that confers twitching motil-
ity (i.e. pilB) was very low in all of the infection sites. This 
result suggested that non-pilus adhesins had an impor-
tant role in these PA infections. This gene (pilB) was only 
detected in strains from UTIs and only from a small num-
ber of strains. Our results were not similar to the results 
of Mitov et al. who found that the prevalence of pilB is 
much higher in isolates from urine, blood, and the res-
piratory tract [22]. In our study, the pilB gene was more 
prevalent among the strains isolated from older patients. 
Older patients have a higher risk of development of UTI; 
strains of PA that are associated with UTIs tend to form 
biofilms and pilB-positive strains produce biofilms [4].
Kiewitz and Tummler’s results suggested that the pilA 
gene is located in the chromosome regions of extended 
interclonal variability and has no high codon adaptation 
indices [16]. Therefore, the expression of this gene may 
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Rapid tests that detect virulence genes may help to 
resolve the increasing problem of the association 
between virulence and resistance. These tests may be 
very helpful for clinicians because they could be used to 
confirm that the virulence markers are present (i.e. in 
blood) before the bacteria can be isolated. 
This study revealed that there was a high prevalence of dif-
ferent virulence genes among clinical strains of PA in south-
ern Poland. These genes may be associated with severe 
infections. Strains isolated from different types of infec-
tions exhibited variant virulence gene patterns. The strains 
isolated from patients with BSIs were especially likely to 
have characteristics associated with high virulence. Under-
standing the contribution of selected virulence genes to 
the outcome of an infection may be important for thera-
peutic management of patients infected with PA. Future 
studies should address these mechanisms of virulence and 
the relationships between virulence and resistance. 
no correlation between the presence of exoU and XDR 
phenotype, nor did we find any resistance to ciprofloxa-
cin and imipenem, as other authors suggested [24, 34]. 
Alkaline protease is an important virulence factor, 
because it promotes the development of bacteria within 
the infected host and interferes with immune system 
[30]. The gene encoding this protease was prevalent in 
the strains isolated from patients with PNU or a BSI, but 
was less prevalent in the strains isolated from patients 
with a UTI. This result suggested that alkaline protease 
may not be significantly involved in the pathogenesis 
of UTI. The urinary tract may not provide the substrate 
required for expression of the aprA gene [30]. 
Most of the clinical isolates carried genes involved in 
phenazine production. The two phenazine genes (phzM, 
phzS) were detected more frequently among isolates 
from BSI samples, compared with isolates from UTI or 
PNU samples. None of the virulence factors genes were 
associated with patient age.
REFERENCES 
[1] Agnello M., Finkel S.E., Wong-Beringer A.: Fitness cost of fluoro-
quinolone resistance in clinical isolates of Pseudomonas aeruginosa 
differs by type III secretion genotype. Front. Microbiol., 2016; 7: 1591
[2] Ajayi T., Allmond L.R., Sawa T., Wiener-Kronish J.P.: Single-nu-
cleotide-polymorphism mapping of the Pseudomonas aeruginosa type 
III secretion toxins for development of a diagnostic multiplex PCR 
system. J. Clin. Microbiol., 2003; 41: 3526-3531
[3] Beceiro A., Tomás M., Bou G.: Antimicrobial resistance and viru-
lence: a successful or deleterious association in the bacterial world? 
Clin. Microbiol. Rev., 2013, 26: 185-230
[4] Chiang P., Habash M., Burrows L.L.: Disparate subcellular locali-
zation patterns of Pseudomonas aeruginosa Type IV pilus ATPases in-
volved in twitching motility. J. Bacteriol., 2005; 187: 829-839
[5] Ciragil P., Söyletir G.: Alginate, elastase and alkaline protease 
production of Pseudomonas aeruginosa strains isolated from various 
body sites. Mikrobiyol. Bul., 2004; 38: 341-347
[6] Di Martino P., Gagniere H., Berry H., Bret L.: Antibiotic resistance 
and virulence properties of Pseudomonas aeruginosa strains from 
mechanically ventilated patients with pneumonia in intensive care 
units: comparison with imipenem-resistant extra-respiratory tract 
isolates from uninfected patients. Microbes Infect., 2002; 4: 613-620
[7] Feltman H., Schulert G., Khan S., Jain M., Peterson L., Hauser A.R.: 
Prevalence of type III secretion genes in clinical and environmental 
isolates of Pseudomonas aeruginosa. Microbiology, 2001; 147: 2659-2669
[8] Ferreira M.L., Dantas R.C., Faria A.L., Goncalves I.R., Silveira de 
Brito C., Queiroz L.L., Gontijo-Filho P.P., Ribas R.M.: Molecular epi-
demiological survey of the quinolone- and carbapenem-resistant 
genotype and its association with the type III secretion system in 
Pseudomonas aeruginosa. J. Med. Microbiol., 2015; 64: 262-271
[9] Finnan S., Morrissey J.P., O’Gara F., Boyd E.F.: Genome diversity 
of Pseudomonas aeruginosa isolates from cystic fibrosis patients and 
the hospital environment. J. Clin. Microbiol., 2004; 42: 5783-5792
[10] Frank D.W.: The exoenzyme S regulon of Pseudomonas aeruginosa. 
Mol. Microbiol., 1997; 26: 621-629
[11] Gaynes R., Edwards J.R., National Nosocomial Infections Surveil-
lance System: Overview of nosocomial infections caused by Gram-
negative bacilli. Clin. Infect. Dis., 2005; 41: 848-854
[12] Greenhagen B.T., Shi K., Robinson H., Gamage S., Bera A.K., Lad-
ner J.E., Parsons J.F.: Crystal structure of the pyocyanin biosynthetic 
protein PhzS. Biochemistry, 2008; 47: 5281-5289
[13] Hamood A.N., Griswold J.A., Duhan C.M.: Production of extracel-
lular virulence factors by Pseudomonas aeruginosa isolates obtained 
from tracheal, urinary tract, and wound infections. J. Surg. Res., 
1996; 61: 425-432
[14] Horvat R.T., Parmely M.J.: Pseudomonas aeruginosa alkaline pro-
tease degrades human gamma interferon and inhibits its bioactivity. 
Infect. Immun., 1988; 56: 2925-2932
[15] Juan C., Peña C., Oliver A.: Host and pathogen biomarkers for 
severe Pseudomonas aeruginosa infections. J. Infect. Dis., 2017; 215 
(Suppl. 1): S44-S51
[16] Kiewitz C., Tümmler B.: Sequence diversity of Pseudomonas aer-
uginosa: Impact on population structure and genome evolution. J. 
Bacteriol., 2000; 182: 3125-3135
[17] Knight D.A., Finck-Barbancon V., Kulich S.M., Barbieri J.T.: Func-
tional domains of Pseudomonas aeruginosa exoenzyme S. Infect. Im-
mun., 1995; 63: 3182-3186
[18] Lee K., Lim Y.S., Yong D., Yum J.H., Chong Y.: Evaluation of the Hodge 
test and the imipenem-EDTA double-disc synergy test for differentiat-
ing metallo-beta-lactamase-producing isolates of Pseudomonas spp. and 
Acinetobacter spp. J. Clin. Microbiol., 2003; 41: 4623-4629
[19] Lomholt J.A., Poulsen K., Kilian M.: Epidemic population struc-
ture of Pseudomonas aeruginosa: Evidence for a clone that is patho-
genic to the eye and that has a distinct combination of virulence 
factors. Infect. Immun., 2001; 69: 6284-6295
759
Pobiega M. et al. – Virulence factors genes and drug resistance...
[34] Sullivan E., Bensman J., Lou M., Agnello M., Shriner K., Wong-
Beringer A.: Risk of developing pneumonia is enhanced by the com-
bined traits of fluoroquinolone resistance and type III secretion 
virulence in respiratory isolates of Pseudomonas aeruginosa. Crit. 
Care Med., 2014; 42: 48-56
[35] Tseng M.N., Chung P.C., Tzean S.S.: Enhancing the stress toler-
ance and virulence of an entomopathogen by metabolic engineer-
ing of dihydroxynaphthalene melanin biosynthesis genes. Appl. 
Environ. Microbiol., 2011; 77: 4508-4519
[36] Vallis A.J., Finck-Barbancon V., Yahr T.L., Frank D.W.: Biological 
effects of Pseudomonas aeruginosa type III-secreted proteins on CHO 
cells. Infect. Immun., 1999; 67: 2040-2044
[37] Vance R.E., Rietsch A., Mekalanos J.J.: Role of the type III secreted 
exoenzymes S, T, and Y in systemic spread of Pseudomonas aeruginosa 
PAO1 in vivo. Infect. Immun., 2005; 73: 1706-1713
[38] Viedma E., Juan C., Acosta J., Zamorano L., Otero J.R., Sanz F., 
Chaves F., Oliver A.: Nosocomial spread of colistin-only-sensitive 
sequence type 235 Pseudomonas aeruginosa isolates producing the 
extended-spectrum β-lactamases GES-1 and GES-5 in Spain. Anti-
microb. Agents Chemother., 2009; 53: 4930-4933
[39] Wolska K., Szweda P.: Genetic features of clinical Pseudomonas 
aeruginosa strains. Pol. J. Microbiol., 2009; 58: 255-260
[40] Zhu H., Conibear T.C., Bandara R., Aliwarga Y., Stapleton F., Will-
cox M.D.: Type III secretion system-associated toxins, proteases, se-
rotypes, and antibiotic resistance of Pseudomonas aeruginosa isolates 
associated with keratitis. Curr. Eye Res., 2006; 31: 297-306
The authors have no potential conflicts of interest to 
declare.
[20] Magiorakos A.P., Srinivasan A., Carey R.B., Carmeli Y., Falagas 
M.E., Giske C.G., Harbarth S., Hindler J.F., Kahlmeter G., Olsson-Liljeq-
uist B., Paterson D.L., Rice L.B., Stelling J., Struelens M.J., Vatopoulos 
A., Weber J.T., Monnet D.L.: Multidrug-resistant, extensively drug-
resistant and pandrug-resistant bacteria: an international expert 
proposal for interim standard definitions for acquired resistance. 
Clin. Microbiol. Infect., 2012; 18: 268-281
[21] Mavrodi D.V., Parejko J.A., Mavrodi O.V., Kwak Y.S., Weller D.M., 
Blankenfeldt W., Thomashow L.S.: Recent insights into the diversity, 
frequency and ecological roles of phenazines in fluorescent Pseu-
domonas spp. Environ. Microbiol., 2013; 15: 675-686
[22] Mitov I., Strateva T., Markova B.: Prevalence of virulence genes 
among bulgarian nosocomial and cystic fibrosis isolates of Pseu-
domonas aeruginosa. Braz. J. Microbiol., 2010; 41: 588-595
[23] Morihara K., Tsuzuki H.: Production of protease and elastase 
by Pseudomonas aeruginosa strains isolated from patients. Infect. 
Immun., 1977; 15: 679-685
[24] Pena C., Cabot G., Gómez-Zorrilla S., Zamorano L., Ocampo-Sosa 
A., Murillas J., Almirante B., Pomar V., Aguilar M., Granados A., Calbo 
E., Rodriguez-Bano J., Rodriguez-López F., Tubau F., Martinez-Mar-
tinez L., Oliver A., Spanish Network for Research in Infectious Dis-
eases (REIPI): Influence of virulence genotype and resistance profile 
in the mortality of Pseudomonas aeruginosa bloodstream infections. 
Clin. Infect. Dis., 2015; 60: 539-548
[25] Pobiega M., Maciąg J., Chmielarczyk A., Romaniszyn D., Pomor-
ska-Wesolowska M., Ziolkowski G., Heczko P.B., Bulanda M., Wojkows-
ka-Mach J.: Molecular characterization of carbapenem-resistant 
Pseudomonas aeruginosa strains isolated from patients with urinary 
tract infections in Southern Poland. Diagn. Microbiol. Infect. Dis., 
2015; 83: 295-297
[26] Pobiega M., Wojkowska-Mach J., Maciag J., Chmielarczyk A., 
Romaniszyn D., Pomorska-Wesolowska M., Ziolkowski G., Heczko 
P.B., Bulanda M.: Virulence and antibiotic resistance of Pseudomonas 
aeruginosa isolated from patients with urinary tract infections in 
Southern Poland. Chemotherapy, 2014; 60: 253-260
[27] Richards M.J., Edwards J.R., Culver D.H., Gaynes R.P.: Nosocomial 
infections in medical intensive care units in the United States. Na-
tional Nosocomial Infections Surveillance System. Crit. Care Med., 
1999; 27: 887-892
[28] Roy-Burman A., Savel R.H., Racine S., Swanson B.L., Revadigar N.S., 
Fujimoto J., Sawa T., Frank D.W., Wiener-Kronish J.P.: Type III protein 
secretion is associated with death in lower respiratory and systemic 
Pseudomonas aeruginosa infections. J. Infect. Dis., 2001; 183: 1767-1774
[29] Rumbaugh K.P., Griswold J.A., Hamood A.N.: Pseudomonas aer-
uginosa strains obtained from patients with tracheal, urinary tract 
and wound infection: variations in virulence factors and virulence 
genes. J. Hosp. Infect., 1999; 43: 211-218
[30] Sabharwal N., Dhall S., Chhibber S., Harjai K.: Molecular detec-
tion of virulence genes as markers in Pseudomonas aeruginosa iso-
lated from urinary tract infections. Int. J. Mol. Epidemiol. Genet., 
2014; 5: 125-134
[31] Schulert G.S., Feltman H., Rabin S.D., Martin C.G., Battle S.E., Rel-
lo J., Hauser A.R.: Secretion of the toxin ExoU is a marker for highly 
virulent Pseudomonas aeruginosa isolates obtained from patients with 
hospital-acquired pneumonia. J. Infect. Dis., 2003; 188: 1695-1706
[32] Sievert D.M., Ricks P., Edwards J.R., Schneider A., Patel J., Srini-
vasan A., Kallen A., Limbago B., Fridkin S., National Healthcare Safety 
Network (NHSN) Team and participating NHSN Facilities: Antimi-
crobial-resistant pathogens associated with healthcare-associated 
infections: Summary of data reported to the National Healthcare 
Safety Network at the Centers for Disease Control and Prevention, 
2009-2010. Infect. Control Hosp. Epidemiol., 2013; 34: 1-14
[33] Simonetti A., Ottaiano E., Diana M.V., Onza C., Triassi M.: Epide-
miology of hospital-acquired infections in an adult intensive care 
unit: results of a prospective cohort study. Ann. Ig., 2013; 25: 281-289
